Medical

HCQ Or Chloroquine +/- Macrolide For COVID-19

Pinterest LinkedIn Tumblr

This observational Lancet study compared ~96,000 patients across 671 international hospitals with a positive COVID-19 diagnosis who received hydroxychloroquine (HCQ) +/- a macrolide (ie, azithro) or chloroquine +/- a macrolide (four total treatment arms) to a control arm that received none of the aforementioned therapies. The primary outcome was In-hospital mortality. The major secondary outcome was de-novo ventricular arrhythmias (we already know HCQ and azithro prolong the QT interval).

Patients were excluded if they received the aforementioned treatments > 48 hours after testing positive, received remdesivir, or were already on mechanical ventilation. The authors found that each of the four treatment arms were independently associated with an increased risk of in-hospital mortality AND de-novo ventricular arrhythmias when compared to the control.

Naturally, one would be skeptical given the observational nature of this study coupled with the fact that many institutions were selecting for the “sickest patients” (ie, those requiring ICU admission) to receive the therapies in question. Perhaps many of these individuals would have died regardless of the therapy they received? However, the authors used a Cox proportional hazard model to account for many of the confounding variables (patient demographics, comorbidities, other medications, disease severity, etc.) in addition to propensity score matching to support the results.

Limitations include a lack of randomization and consideration for more granular data (no description of how treatment regimens were dosed/timed in the first 48 hours, etc.). Given the observational design, one CANNOT infer causation either.

So yes, in conclusion, we really don’t have a great alternative currently. Plenty of work is being done regarding vaccine development, but in the interim, prevention is the best therapy.

This article has since been retracted by the NEJM and Lancet. In the New England Journal retraction statement, the study authors wrote, “Because all the authors were not granted access to the raw data and the raw data could not be made available to a third-party auditor, we are unable to validate the primary data sources underlying our article.” They apologized “for the difficulties that this has caused.”

2 Comments

  1. The Lancet has retracted the linked study/article after questions raised by The Guardian over SurgiSphere’s involvement in obtaining (or fabricating) the study’s data. NEJM then retracted their similar study for similar reasons.

Write A Comment

Pin It